High-dose peretinoin as adjunctive therapy in hepatitis C-positive patients with hepatocellular carcinoma following curative therapy (surgical resection or transcutaneous radiofrequency ablation).

Trial Profile

High-dose peretinoin as adjunctive therapy in hepatitis C-positive patients with hepatocellular carcinoma following curative therapy (surgical resection or transcutaneous radiofrequency ablation).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Peretinoin (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2011 New source identified and integrated: University Hospital Medical Information Network - Japan record UMIN000006728.
    • 24 Jan 2011 Results from a subgroup analysis presented at the ASCO Gastrointestinal Cancers Symposium in January 2011 (abstract 165), and reported in a Kowa Pharmaceutical media release.
    • 20 Jan 2011 Results of subanalysis to be presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011, according to a Kowa media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top